LPA181 in Spinal Cord Injury & neuropathic pain

World wide, over 20.000 cases of Spinal Cord Injury (SCI) are registered every year, mainly due to traffic accidents. In most cases those lesions derive in very serious mobility loses, either affecting leg mobility (paraplegia) or body and arms mobility (tetraplegia) very badly affecting the quality of life of patients and of their relatives. Currently there are not effective treatments leading to the recovery of the mobility of patients suffering from SCI, so there is a very important medical need uncovered in this field.

LPA181 is a synthetic monounsaturated fatty acid derivative which shows promise in the treatment of Spinal Cord Injury (SCI), Neuropathic pain and other SCI-related lesions, such as sensitivity loss.

As of February 2016, rights for LPA181 program have been out-licensed to Neurofix, a Spanish biopharmaceutical company.

Supported by: